Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Glasdegib Daurismo 25mg, 100mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2018 In Use
J0642 Levoleucovorin Khapzory 0.5mg Ancillary Therapy Chemoprotective Antidote No 2018 Oct 1, 2019 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
J9036 Bendamustine HCL Belrapzo 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2018 Jul 1, 2019 In Use
J9118 Calaspargase pegol-mknl Asparlas 10 units Chemotherapy Miscellaneous Agent Enzyme No 2018 Oct 1, 2019 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
J9269 Tagraxofusp-erzs Elzonris 10mcg Immunotherapy Recombinant Fusion Protein IL3/CD123 No 2018 Oct 1, 2019 In Use
NA Ivosidenib Tibsovo 250mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2018 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct 1, 2019 In Use
NA Entrectinib Rozlytrek 100mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Yes 2019 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 Jul 1, 2020 In Use
J9044 Bortezomib Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2019 Nov 3, 2019 Dec 21, 2022 In Use
J9309 Polatuzumab Vedotin Polivy 1mg Immunotherapy Drug Antibody Conjugate CD79b No 2019 Jan 1, 2020 In Use
NA Selinexor Xpovio 20mg, 40mg, 50mg, 60mg Chemotherapy Enzyme Inhibitor XPO1 Yes 2019 In Use
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 Mar 31, 2020 Jul 1, 2020 No Longer Used
J1456 Fosaprepitant (Teva) Fosaprepitant (Teva) 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2019 Dec 21, 2022 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.